EGF and cancer: To analyze signaling pathways that could mediate the effects of AZA1 mediated Rac1/Cdc42 inhibition, we examined the activity of the downstream effector PAK by evaluating PAK phosphorylation in EGF-stimulated cancer cells following AZA1 treatment.